LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition

ME Staff 8-k
-
0
LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition

LOXO ONCOLOGY,INC. (NASDAQ:LOXO) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On November8, 2018, Loxo Oncology,Inc. (“Loxo Oncology”) issued a press release announcing its financial results for the quarterly period ended September30, 2018. A copy of the press release is attached as Exhibit99.1 to this Current Report on Form 8-K.

The information in this Item 2.02, including Exhibit99.1 to this Current Report on Form8-K, shall not be deemed to be “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section or Sections11 and 12(a)(2)of the Securities Act of 1933, as amended. The information contained in this Item 2.02 and in the accompanying Exhibit99.1 shall not be incorporated by reference into any registration statement or other document filed by Loxo Oncology with the Securities and Exchange Commission, whether made before or after the date of this Current Report on Form8-K, regardless of any general incorporation language in such filing (or any reference to this Current Report on Form8-K generally), except as shall be expressly set forth by specific reference in such filing.

Item 2.02 Submission of Matters to a Vote of Security Holders.

This disclosure corrects our previous reporting under Item 2.02 of the Current Report on Form8-K filed by Loxo Oncology on June14, 2018 to report the results of proposal number 4, the non-binding advisory vote on the frequency of future advisory votes to approve named executive officer compensation. On June13, 2018, the Company held its 2018 Annual Meeting of Stockholders and the following proposal was adopted:

4. Adoption of a non-binding advisory vote on the frequency of future advisory votes to approve named executive officer compensation. The Company’s Board of Directors supported the advisory resolution, and will include a non-binding advisory shareholder vote on its executive compensation every year until the next vote on the frequency of shareholder votes on the compensation of executives.

OneYear

TwoYears

ThreeYears

SharesAbstaining

BrokerNon-Votes

26,558,284

509,490

183,709

1,372,632

Item 2.02 Regulation FD.

Loxo Oncology is furnishing a copy of its current corporate presentation, which is attached hereto as Exhibit99.2. Loxo Oncology undertakes no obligation to update, supplement or amend the materials attached hereto as Exhibit99.2.

The information furnished with this report, including Exhibit99.2, shall not be deemed “filed” for purposes of Section18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Item 2.02 Financial Statements and Exhibits

(d)Exhibits.


Loxo Oncology, Inc. Exhibit
EX-99.1 2 a18-39556_1ex99d1.htm EX-99.1 Exhibit 99.1     Loxo Oncology Reports Third Quarter 2018 Financial Results   – Larotrectinib New Drug Application (NDA) PDUFA date is November 26,…
To view the full exhibit click here

About LOXO ONCOLOGY,INC. (NASDAQ:LOXO)

Loxo Oncology, Inc. is a United States-based biopharmaceutical company. The Company is engaged in developing selective medicines for patients with genetically defined cancers. Its pipeline focuses on cancers that are dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer. Its pipeline includes LOXO-101, LOXO-195, Rearranged During Transfection (RET) Program and Fibroblast Growth Factor Receptor (FGFR) program. LOXO-101 is a selective inhibitor of tropomyosin receptor kinases (TRK) for the treatment of patients with soft tissue sarcoma. LOXO-195 is a selective TRK inhibitor capable of addressing potential mechanisms of acquired resistance that may emerge in patients receiving LOXO-101 or multikinase inhibitors with anti-TRK activity. It has designed a series of RET inhibitors that optimize on-target potency for RET gene fusions, mutations and clinically-identified resistance mutations. It is designing FGFR1-sparing FGFR inhibitor.